Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

PolyMedix Obtains USAN Approval For Generic Name Of Brilacidin For PMX-30063

6/12/2012 4:59 PM ET

PolyMedix Inc. (PYMX) announced that the United States Adopted Names or USAN Council, in consultation with the World Health Organization or WHO International Nonproprietary Names Expert Committee, has approved the use of the nonproprietary generic name "brilacidin" (pronounced bri-la-ci-din) for PMX-30063, a first-in-class defensin mimetic antibiotic.

PolyMedix said it recently announced positive results from a Phase 2 clinical study with brilacidin as an intravenous treatment in patients with acute bacterial skin and skin structure Staph aureus infections.

The company said that the USAN Council has also approved the use of the nonproprietary generic name "delparantag" (pronounced del-par-an-tag) for PMX-60056, PolyMedix's first-in-class anticoagulant reversing agent.

Click here to receive FREE breaking news email alerts for PolyMedix Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Publishing and design software maker Adobe Systems Inc. said Tuesday after the markets closed that its second quarter profit fell 66% from last year, hurt by lower revenue as well as higher costs and expenses. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations and its quarterly revenue was in line with analysts' forecast. Stocks showed a strong upward move over the course of the trading day on Tuesday, adding to the gains posted in the previous session. The rally came even as traders expressed some uncertainty ahead of tomorrow's Federal Reserve announcement. The major averages gave back some ground going into the close but remained firmly in positive territory. In a potential roadblock to comprehensive immigration reform legislation, House Speaker John Boehner, R-Ohio, indicated Tuesday that he would not bring a bill to the floor unless it is supported by a majority of House Republicans.
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.